Patient with positive visk of Cancer before treatment.



Doctor Name: Dr. Kalpana Shekawath Patient Name: Mrs Mona Kalra

1 . J. 16 30

Date: 26/03/2019

Description: Mrs Mona Kalra, 54 years old, is showing EpCAM & Cytokeratin POSITIVE expression. The sample was received for analysis on 13.03.2019 was a sample of 10 ml of whole blood sent in MERISISTM CTC Kit that contained sodium citrate as anti-coagulant.

We isolated the cells using MERISISTM CTC Kit with a density gradient gel that isolates cancer cells from normal cells after centrifugation and positive and negative selection using multiple cell markers.

Results:

Table of markers:

CD45 positive cells (Hematologic origin cells)		CD45 negative cells (non Hematologic origin)	
OCT-4	POSITIVE	EpCam	POSITIVE
SOX2	POSITIVE	CD31	NEGATIVE
CD45	POSITIVE	Pan CK	POSITIVE
CD133	POSITIVE	CK17	POSITIVE
		Nanog	NEGATIVE

Index of marker: CD133 & CD45: Hematologic origin cell marker, OCT - 4, Sox -2; CD31: Endothelial cell membrane antigen, EpCAM: Epithelial origin marker, PanCK: Epithelial origin marker, CK17: Cytokeratin


The final results after the isolation procedure are presented below:

The concentration of these cells was isolated ~6 cells/10ml, SD +/- 1 cell.

We notice that after isolation procedure there are CTCs observed. It is therefore suggested that Mrs Mona Kalra, has high risk of cancer hence we suggest to undergo medical checkup with oncologist. We recommend monitoring and repeating the tests after 2 to 3 Months or after treatment.

CLINICAL RISK	MARKERS	Function	RESULTS	OUTCOME
Clinical risk	EpCAM Positive	Indicates high Risk of Lung,	~ 6 cells/10 ml	CTC Positive
observed.	CK17 Positive	Colon, Prostate cancers	141	>5 cells/ 10 ml

S. Santhost Dr. Santhosh Gopal



Doctor Name: Dr. Kalpana Shekawath Patient Name: Mona

Date: 06/07/2019

Description: Mona, 55 years old is showing EpCAM & CK17 NEGATIVE expression. The sample was sent to us for analysis on 28th June 2019, 10ml of whole blood was sent in MERISIS™ CTC Kit that contained

We isolated the cells using MERISIS™ CTC Kit with a density gradient gel that isolates cancer cells from we isolated the cells using a reaction. Cite Kit with a density gradient get that isolates cancer cells i normal cells based on specific gravity and size, after centrifugation and positive and negative selection as multiple cell markers.

Results:

CD45 positive cells (Hematologic origin cells)		Of markers: CD45 n	egative cells
OCT-4	POSITIVE	EpCam	
CD133	POSITIVE	CD31	NEGATIVE
		PanCK	NEGATIVE
			NEGATIVE
		CK17	NEGATIVE
		MUC1	NEGATIVE

Index of marker: CD133 & CD45: Hematologic origin cell marker, MUC 1: Polymorphic epithelial mucin; OCT – 4, Sox -2; CD31: Endothelial cell membrane antigen, EpCAM: Epithelial origin marker, PanCK: Epithelial origin marker, CK17: Cytokeratin

The final results after the isolation procedure are presented below: The concentration of these cells was isolated ~2 cells/10ml, SD +/-2 cell

We notice that after isolation procedure there are no significant CTCs observed. We recommend medical opinion, checkup monitoring and repeating the tests after 2 to 3 Months.

CLINICAL RISK MARKERS Function RESULTS OUTCOME Indicates no Risk LOW RISK LOW RISK NEGATIVE of Lung, Colon, Prostate cancers CK17 etc. NEGATIVE <5cells/10 ml

Sincerely.

Dr. Kaushik D. Deb

Index of circulating cells number:

Lung cancer: <10cells/ml, Prostate cancer < 20cells/ml, Colon cancer: <7cells/ml
(If over Limit: Advanced or Progression of Disease, If Less than limit: Early disease or disease is responding to a treatment plan). Disclaimer: This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dommant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.

No test is 100% accurate.

860/A, 2rd floor, Karnataka Bank Building, Bommasandra, Jiganl ink road, Bangalore
7e:.080 27853022

Websit: www.diponed.com E-mail info@diponed.com